Glycosylation of recombinant proteins is best achieved using:
Mammalian expression systems are best source for producing therapeutic glycoproteins that require authentic post-translational modifications to be biologically active and non-immunogenic. Enzymes localized in endoplasmic reticulum and Golgi apparatus catalyze N-linked glycosylation at Asn-X-Ser/Thr motifs via oligosaccharyltransferase, trimming by glucosidases, addition of complex sialylated structures by sialyltransferases, O-glycosylation, formation of disulfide bonds by protein disulfide isomerase and Ero1, gamma-carboxylation, and proper folding assisted by chaperones BiP, calnexin, calreticulin. Bacterial systems such as Escherichia coli lack glycosylation machinery, produce proteins as insoluble inclusion bodies needing refolding, and add non-human metabolites. Yeast Saccharomyces can glycosylate but hypermannosylates leading to rapid clearance and immunogenicity. Cell-free extracts have limited capacity for disulfide bond formation and complex modifications. Therefore Chinese hamster ovary CHO, HEK293, and BHK lines dominate biopharmaceutical manufacturing of monoclonal antibodies, erythropoietin, clotting factors VIII/IX, and viral vectors where glycan profile dictates half-life, efficacy, and safety, justifying rigorous glycoanalysis during process development. Bioengineering efforts aim to humanize glycosylation pathways in CHO to produce afucosylated antibodies enhancing effector function. This knowledge strengthens laboratory safety, protocol reproducibility, and regulatory compliance critical for translational research and clinical applications, ensuring reliable data and workforce protection.
Ref: Wurm FM Nat Biotechnol 2004 CHO mammalian cell protein production; Lodish MBoC 8th Ed Ch.13 Protein glycosylation and ER quality control.